September 2022 Issue: Mirati Therapeutics (SYM: MRTX)
- Dylan Jovine
- Wednesday, September 21, 2022
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
September 2022 Issue: Mirati Therapeutics (SYM: MRTX)
- Dylan Jovine
- Wednesday, September 21, 2022
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
Get FREE Weekly Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
